116 results on '"Stein, Mark A."'
Search Results
2. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
3. 41.1 Understanding the Impact of ADHD Familiality and Genetics on ADHD Medication Response and Optimization
4. Editorial: Attention-Deficit/Hyperactivity Disorder, Stimulant Medication and Criminality: Commentary and Caution
5. Editorial: Treating Attention-Deficit/Hyperactivity Disorder in Preschool-Age Children With Stimulants: Modest Effects in Young Children With Big Problems
6. Editorial: Longitudinal Associations Between Sleep and ADHD Symptoms: ADHD Is a 24-Hour Disorder
7. NEUROPHYSIOLOGY OF ADHD IN EEG, EYE TRACKING, PUPIL RESPONSE, BREADTH OF PERCEPTION, AND NEUROFEEDBACK AND TRIGEMINAL NERVE STIMULATION (TNS) EFFECTS: NEW ICAN AND OTHER DATA
8. 16.2 Dopamine Transporter and CYP2D6 Gene Effects on ADHD in the Methylphenidate and Atomoxetine Crossover Study
9. Attention Deficit Hyperactivity Disorder Medications and Sleep
10. Measurement Informed Care in Attention-Deficit/Hyperactivity Disorder (ADHD)
11. Predictors of Treatment Engagement and Outcome Among Adolescents With Attention-Deficit/Hyperactivity Disorder: An Integrative Data Analysis
12. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
13. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
14. MANAGING ADOLESCENTS WITH ADHD: DEVELOPMENTAL ISSUES, EMERGING COMORBIDITY, AND THE IMPACT OF COVID-19
15. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
16. Telemedicine in management of genitourinary malignancies: Patient and physician perspectives
17. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
18. Dopamine Transporter and CYP2D6 Genotype Associations With ADHD Treatment Response: Results From the Methylphenidate-Atomoxetine Crossover Study (MACRO)
19. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
20. 5.16 LIFESTYLE ENHANCEMENT FOR ADHD PROGRAM (LEAP): HEALTH-FOCUSED PARENT TRAINING INTERVENTION EFFECTS ON PHYSICAL ACTIVITY AND SCREEN TIME BEHAVIORS AMONG CHILDREN WITH ADHD
21. 9.1 A SHARED DECISION-MAKING APPROACH TO EVALUATING, SEQUENCING, AND COMBINING INTERVENTIONS IN TEENAGERS WITH ADHD
22. BARRIERS AND SOLUTIONS TO TREATING TEENAGERS WITH ADHD: PERSPECTIVES FROM CLINICAL RESEARCHERS
23. Seizure risk, methylphenidate, and ADHD: reassuring news
24. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)
25. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study
26. The Effects of Anesthesia on the Pediatric Developing Brain: Strategies to Reduce Anesthesia Use in Pediatric MRI and Nursing's Role in Driving Patient Safety
27. 6.69 TREATING MOTHERS AND FATHERS WITH ADHD WITH STIMULANT MEDICATION AND PARENT TRAINING: EFFECTS ON PARENTING AND GLOBAL IMPROVEMENT
28. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases
29. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
30. Editorial: Is Less Parent Training “Not Inferior” to More?
31. Reducing Anesthesia Use for Pediatric Magnetic Resonance Imaging: The Effects of a Patient- and Family-Centered Intervention on Image Quality, Health-care Costs, and Operational Efficiency
32. Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases
33. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
34. 7.2 Losing Sleep Over ADHD and Stimulants?
35. 25.3 A Pilot Smart Targeting Multiplex ADHD Families: Lessons Learned
36. Refining treatment choices for ADHD
37. Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%
38. 6.36 Comparing Health Behaviors in Youth With Neurodevelopmental Disorders vs. Asthma or Normative Controls
39. 42.3 Diagnostic Dilemmas With Subclinical or Mild Attention-Deficit/Hyperactivity Disorder
40. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine
41. 855. Response to Methylphenidate and Atomoxetine in Children with ADHD: Pharmacogenetic Predictors
42. 856. Methylphenidate vs. Atomoxetine in Youth with ADHD: Comparative Effectiveness and Preference following Treatment with both Medications
43. A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% Formulation
44. Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)
45. A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
46. Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies
47. Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity Reaction
48. 6.40 EXAMINATION OF THE SLUGGISH COGNITIVE TEMPO CONSTRUCT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
49. 6.39 AFFECTIVE INSTABILITY AND OPPOSITIONAL DEFIANCE IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: TREATMENT EFFECTS
50. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.